All In Biotech

NDA 018692 · Hospira

Marcaine

Bupivacaine Hydrochloride · Spinal

Last checked: Nov 19, 2026Latest source record: Sep 28, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1984

May 4, 1984

Approved uses

1

Original approval plus efficacy supplements

Registered trials

2,836

341 Phase 3, 228 recruiting

FAERS reports

4,689

2,689 serious, 313 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 23, 2026.

MARCAINE SPINAL is indicated for subarachnoid injection in adults for the production of subarachnoid block (spinal anesthesia). MARCAINE SPINAL is an amide-local anesthetic indicated in adults for subarachnoid injection for the production of subarachnoid block (spinal anesthesia). ( 1 )

Mechanism: Bupivacaine blocks the generation and the conduction of nerve impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. In general, the progression of anesthesia is related to the diameter, myelination, and conduction velocity of affected nerve fibers. Clinically, the order of loss of nerve function is as follows: (1) pain, (2) temperature, (3) touch, (4) proprioception, and (5) skeletal muscle tone.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 4, 1984 Original approval · Type 3 - New Dosage Form Review
1 products under this application
  • MARCAINE · BUPIVACAINE HYDROCHLORIDE 0.75% · INJECTABLE, SPINAL · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Bupivacaine" as an intervention, any sponsor and status, largest first.

All 2,836 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective1,616
  • anaesthetic complication283
  • off label use246
  • pain219
  • hypoaesthesia209
  • maternal exposure during pregnancy209
  • hypotension199
  • headache177
  • dyspnoea168
  • dizziness154
  • nausea145
  • condition aggravated143

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200491
200577
200697
200765
200880
2009115
201086
2011100
201292
201398
2014122
2015191
2016617
2017385
2018244
2019240
2020239
2021194
2022401
2023251
2024325
2025333
2026246

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

  • Current · updated Nov 9, 2026

    Marcaine, Injection, 0.75% 15 mg/2 mL (NDC 0409-1761-62).

  • Current · updated Nov 9, 2026

    Marcaine, Injection, 0.75% 15 mg/2 mL (7.5 mg/mL) in Dextrose 8.25% (NDC 0409-1761-10). Other

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Marcaine (Bupivacaine HCl)

2024 spending

$262

Beneficiaries

16

18 claims

Per beneficiary

$16

$0.16 per unit

View as table
YearSpending
2020$0
2021$382
2022$0
2023$297
2024$262

Part D: Marcaine (Bupivacaine HCl/PF)

2024 spending

$302

Beneficiaries

24

30 claims

Per beneficiary

$13

$0.53 per unit

View as table
YearSpending
2020$0
2021$263
2022$161
2023$694
2024$302

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 5,921 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.